Zantac burns big pharma
As Zantac litigation risk wipes $43bn off public company valuations are investors right to be worried?
Another strike for biotech: China
Use of an auditor that cannot be inspected by the US regulator takes centre stage as Chinese biotech stocks fall.
How China applicants could avoid the sintilimab scenario
A US adcom savages sintilimab, but the biggest problems identified might be sintilimab-specific.
Biogen hints at jobs cuts unless government pays up
An analyst call over the Aduhelm coverage debacle sees Biogen threaten more cost cutting.
Aduhelm verdict puts the heat on Biogen – and on the FDA
The US Centers for Medicare & Medicaid Services’ national coverage determination for Biogen’s Aduhelm makes for uncomfortable reading.
Your 2022 wildcard predictions revealed
Could Aduhelm be pulled? Will Incyte get acquired? Here are some of your wildest New Year predictions.
